CL2020002199A1 - Compuesto de anillo de metillactama y uso farmacéutico del mismo. - Google Patents

Compuesto de anillo de metillactama y uso farmacéutico del mismo.

Info

Publication number
CL2020002199A1
CL2020002199A1 CL2020002199A CL2020002199A CL2020002199A1 CL 2020002199 A1 CL2020002199 A1 CL 2020002199A1 CL 2020002199 A CL2020002199 A CL 2020002199A CL 2020002199 A CL2020002199 A CL 2020002199A CL 2020002199 A1 CL2020002199 A1 CL 2020002199A1
Authority
CL
Chile
Prior art keywords
methylactam
pharmaceutical use
ring compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
CL2020002199A
Other languages
English (en)
Inventor
Tomoya Miura
Yoshinori Tamatani
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CL2020002199A1 publication Critical patent/CL2020002199A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un objetivo de la presente invención es proporcionar un compuesto de anillo de metillactama que tiene una actividad inhibidora de SGLT1 y es útil para un fármaco, o una sal farmacéuticamente aceptable del mismo, una composición farmacéutica que lo comprende, y uso farmacéutico del mismo; se proporciona un compuesto de la Fórmula [I]: o una sal farmacéuticamente aceptable del mismo, una composición farmacéutica que lo comprende, y uso farmacéutico del mismo.
CL2020002199A 2018-03-01 2020-08-26 Compuesto de anillo de metillactama y uso farmacéutico del mismo. CL2020002199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018036307 2018-03-01

Publications (1)

Publication Number Publication Date
CL2020002199A1 true CL2020002199A1 (es) 2020-12-18

Family

ID=67806229

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002199A CL2020002199A1 (es) 2018-03-01 2020-08-26 Compuesto de anillo de metillactama y uso farmacéutico del mismo.

Country Status (21)

Country Link
US (3) US11014910B2 (es)
EP (1) EP3760624A4 (es)
JP (3) JP7206132B2 (es)
KR (1) KR102795351B1 (es)
CN (1) CN111757877B (es)
AR (1) AR114418A1 (es)
AU (1) AU2019227770B2 (es)
BR (1) BR112020016788A2 (es)
CA (1) CA3087859A1 (es)
CL (1) CL2020002199A1 (es)
IL (1) IL276311B2 (es)
MA (1) MA52427A (es)
MX (1) MX2020009070A (es)
MY (1) MY205197A (es)
PE (1) PE20210123A1 (es)
PH (1) PH12020551340A1 (es)
SA (1) SA520420037B1 (es)
SG (1) SG11202007120UA (es)
TW (1) TWI805699B (es)
WO (1) WO2019168096A1 (es)
ZA (1) ZA202004600B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
MX2020010433A (es) 2018-04-04 2020-10-28 Japan Tobacco Inc Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos.
US20230210831A1 (en) * 2019-09-04 2023-07-06 Japan Tobacco Inc. Chronic kidney disease treatment or prevention method
AU2020341926B2 (en) * 2019-09-04 2026-02-26 Shionogi & Co., Ltd. Therapeutic or prophylactic method for diabetes using combination medicine
CN115209919B (zh) * 2020-03-19 2024-12-31 日本烟草产业株式会社 慢性心衰的治疗或预防方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657282A (en) * 1969-01-23 1972-04-18 Merck & Co Inc Carboxyepoxyethyl-1-phosphonic acid and derivatives
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE602004028800D1 (en) 2003-02-07 2010-10-07 Daiichi Sankyo Co Ltd Pyrazolderivat
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd 7員複素環誘導体
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
JP2008505905A (ja) 2004-07-07 2008-02-28 メルク エンド カムパニー インコーポレーテッド ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法
CA2586358C (en) 2004-11-16 2015-11-24 Gw Pharma Limited Use of tetrahydrocannabivarin (thcv) as neutral antagonist of the cb1 cannabinoid receptor
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP4137956B2 (ja) 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
AU2006255944B2 (en) 2005-06-08 2010-03-04 Japan Tobacco Inc. Heterocyclic compound
ZA200800142B (en) * 2005-06-08 2009-05-27 Japan Tobacco Inc Heterocyclic compound
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
WO2007098826A2 (en) 2006-01-18 2007-09-07 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
KR20090007606A (ko) * 2006-04-27 2009-01-19 솔베이 파머슈티컬스 게엠베하 CBx 칸나비노이드 수용체 조절제들 및 칼륨 채널 조절제들을 포함하는 약학적 조성물들
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
EP2121619A2 (en) 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
EP2102165A2 (en) 2006-11-24 2009-09-23 AC Immune S.A. N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
CN101652377A (zh) * 2007-04-02 2010-02-17 泰拉科斯有限公司 苄基化糖苷衍生物及其用法
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
TW201006832A (en) 2008-07-15 2010-02-16 Novartis Ag Organic compounds
EP2560966B1 (en) 2010-03-30 2021-01-06 Verseon International Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
MY193765A (en) * 2015-02-16 2022-10-27 Univ Queensland Sulfonylureas and related compounds and use of same
US11858922B2 (en) * 2016-02-16 2024-01-02 The University Of Queensland Sulfonylureas and related compounds and use of same
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
MX2020010433A (es) 2018-04-04 2020-10-28 Japan Tobacco Inc Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos.

Also Published As

Publication number Publication date
MY205197A (en) 2024-10-07
RU2020131756A (ru) 2022-03-28
CA3087859A1 (en) 2019-09-06
ZA202004600B (en) 2022-03-30
CN111757877A (zh) 2020-10-09
PE20210123A1 (es) 2021-01-19
AR114418A1 (es) 2020-09-02
EP3760624A4 (en) 2021-11-03
TWI805699B (zh) 2023-06-21
MA52427A (fr) 2021-01-06
SA520420037B1 (ar) 2024-07-28
IL276311B2 (en) 2023-10-01
US20190352284A1 (en) 2019-11-21
EP3760624A1 (en) 2021-01-06
TW202000660A (zh) 2020-01-01
KR20200128033A (ko) 2020-11-11
US20240174646A1 (en) 2024-05-30
KR102795351B1 (ko) 2025-04-16
PH12020551340A1 (en) 2021-05-31
MX2020009070A (es) 2020-10-08
JP2023026566A (ja) 2023-02-24
JP2025026615A (ja) 2025-02-21
AU2019227770A1 (en) 2020-07-09
US11014910B2 (en) 2021-05-25
IL276311A (en) 2020-09-30
JP7206132B2 (ja) 2023-01-17
AU2019227770B2 (en) 2023-10-05
WO2019168096A1 (ja) 2019-09-06
JP2019151627A (ja) 2019-09-12
IL276311B1 (en) 2023-06-01
SG11202007120UA (en) 2020-08-28
BR112020016788A2 (pt) 2021-01-12
CN111757877B (zh) 2023-10-27
US20220064148A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
MX2018005708A (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7.
MX2016013908A (es) Novedoso compuesto de 1,2,4-triazina disustituida.
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX390747B (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR103680A1 (es) Inhibidores selectivos de bace1
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
CR20180496A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015030399B8 (pt) Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.
UY36124A (es) Derivados de carboxamida
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CL2020002188A1 (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico.
BR112021011325A2 (pt) Derivados de rapamicina
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
MX2018008153A (es) Derivados de c-glicósido que tienen anillos de fenilo condensado o sales farmacéuticamente aceptables de los mismos, metodo para prepararlos y composición farmacéutica que los contiene.